{"filing":{"accession_number":"0001015820-26-000056","cik":"0001015820","ticker":"QGEN","company_name":"QIAGEN N.V.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-30","primary_document":"a08242026ceoappointment.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1015820/000101582026000056/a08242026ceoappointment.htm"},"events":[{"id":32118,"run_id":29506,"accession_number":"0001015820-26-000056","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"The exhibit announces the appointment of Jonathan M. Pratt as Chief Executive Officer of QIAGEN, effective September 1, 2026, succeeding Thierry Bernard. This is a material executive appointment at the highest level of the organization. The disclosure includes Pratt's extensive background (25+ years in life sciences and laboratory technologies, most recently as CEO of Filtration Group), the Supervisory Board's unanimous endorsement, and his planned proposal for shareholder approval as Managing Director at an Extraordinary General Meeting in Q4 2026. The appointment of a new CEO is a material event affecting investor assessment of company leadership and strategic direction.","company_name":"QIAGEN N.V.","ticker":"QGEN","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":35208,"accession_number":"0001015820-26-000056","item_number":"EX-99.1","item_title":"exhibit991ceoappointment08.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The exhibit announces the appointment of Jonathan M. Pratt as Chief Executive Officer of QIAGEN, effective September 1, 2026, succeeding Thierry Bernard. This is a material executive appointment at the highest level of the organization. The disclosure includes Pratt's extensive background (25+ years in life sciences and laboratory technologies, most recently as CEO of Filtration Group), the Supervisory Board's unanimous endorsement, and his planned proposal for shareholder approval as Managing Director at an Extraordinary General Meeting in Q4 2026. The appointment of a new CEO is a material event affecting investor assessment of company leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:04:11.975576+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35208,"accession_number":"0001015820-26-000056","item_number":"EX-99.1","item_title":"exhibit991ceoappointment08.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The exhibit announces the appointment of Jonathan M. Pratt as Chief Executive Officer of QIAGEN, effective September 1, 2026, succeeding Thierry Bernard. This is a material executive appointment at the highest level of the organization. The disclosure includes Pratt's extensive background (25+ years in life sciences and laboratory technologies, most recently as CEO of Filtration Group), the Supervisory Board's unanimous endorsement, and his planned proposal for shareholder approval as Managing Director at an Extraordinary General Meeting in Q4 2026. The appointment of a new CEO is a material event affecting investor assessment of company leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:04:11.975576+00:00","company_name":"QIAGEN N.V.","ticker":"QGEN","filing_date":"2026-09-08"}]}